Old Web
English
Sign In
Acemap
>
Paper
>
Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study)
Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study)
2018
Brian Steingo
Celia Oreja-Guevara
Raed Alroughani
David Brassat
Alexey Boyko
Pamela A. McCombe
Bart Van Wijmeersch
David Margolin
Maria Melanson
Nadia Daizadeh
C. E. Rodriguez
Patrick Vermersch
Keywords:
Diabetes mellitus
Physical therapy
Topaz
Alemtuzumab
Pediatrics
Medicine
5 year follow up
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]
map